

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibilities for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CONCORD HEALTHCARE GROUP CO., LTD.*

美中嘉和醫學技術發展集團股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2453)

VOLUNTARY ANNOUNCEMENT TERMINATION OF VOTING PROXY ARRANGEMENT

This announcement is made by Concord Healthcare Group Co., Ltd.* (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis. Unless otherwise stated, capitalized terms used herein shall have the same meanings as those defined in the prospectus of the Company dated December 29, 2023 (the “**Prospectus**”).

BACKGROUND

As disclosed in the Prospectus, Shanghai Medstar (one of the Controlling Shareholders), as a proxyholder on the one hand (the “**Proxyholder**”), and each of (i) Shanghai Guanyou Enterprise Management Center (Limited Partnership) (上海冠佑企業管理中心(有限合夥)) (“**Shanghai Guanyou**”), (ii) Changsheng Assets Co., Ltd. (長生資產有限責任公司) (“**Changsheng Assets**”) and (iii) Shanghai Xinhe Enterprise Management Center (Limited Partnership) (上海信荷企業管理中心(有限合夥)) (“**Shanghai Xinhe**”), entered into a power of attorney on December 1, 2020, April 29, 2021 and April 7, 2022, respectively, pursuant to which each of them had confirmed and agreed that they had and would continue to, for so long as they are interested in the Shares, defer their voting rights to Shanghai Medstar at the Shareholders’ meetings of our Company, and that any exercise of the aforementioned voting rights and the signing of documents by Shanghai Medstar shall be deemed as the actions of such shareholders themselves. In addition, each of (iv) Hangzhou Lanhai Youfang Equity Investment Fund Partnership (Limited Partnership) (杭州藍海有方股權投資基金合夥企業(有限合夥)) (“**Lanhai Youfang**”) and (v) Ms. TIAN Yuan (as proxy granters on the other hand, collectively, the “**Proxy Granters**”), entered into a power of attorney on June 30, 2023, pursuant to which each of them had confirmed and agreed that, for a period of one year commencing from the date of execution of the power of attorney, each of them deferred their voting rights to the Proxyholder at the Shareholders’ meetings of our Company, and that any exercise of the aforementioned voting rights and the signing of documents by the Proxyholder shall be deemed as the actions of such Proxy Granters themselves. In June 2024, each of Lanhai Youfang and Ms. TIAN Yuan entered into a supplemental power of attorney with the Proxyholder, pursuant to which, each of the original power of attorney entered into by Lanhai Youfang and Ms. TIAN Yuan dated June 30, 2023 would be extended to September 30, 2024 (collectively, the “**Voting Proxy Arrangement**”).

Upon entering into the Voting Proxy Arrangement and up to July 31, 2024, being the date of the Proxy Termination (as defined below), Shanghai Medstar (i) was directly interested in 192,274,636 Domestic Shares, (ii) was indirectly interested in the 28,115,800 H Shares held by Tianjin Concord, which is wholly owned by Shanghai Medstar, and the 13,333,332 Domestic Shares held by Shanghai Xinhe by holding 72.73% partnership interests in Shanghai Xinhe as a limited partner, and (iii) was entitled to the voting rights attached to the 30,161,390 H Shares and 6,666,666 Domestic Shares pursuant to the Voting Proxy Arrangement entered into with the Proxy Granters, representing approximately 37.77% of the Company's total issued share capital and voting rights of the Company's issued Shares in general meetings. For more details, please refer to the sections headed "History, Development and Corporate Structure – Voting Proxy Arrangement" and "Relationship with Our Controlling Shareholders" in the Prospectus.

TERMINATION OF VOTING PROXY ARRANGEMENT

On July 31, 2024, the Company entered into a memorandum on termination of Voting Proxy Arrangement with each of Proxy Granters, and terminated the Voting Proxy Arrangement with such parties with immediate effect (the "**Proxy Termination**"). Upon the Proxy Termination, Shanghai Medstar will continue to be interested in 205,607,968 Domestic Shares and 28,115,800 H Shares, representing 32.63% of the Company's total issued share capital and voting rights of the Company's issued Shares in general meetings. Since the CCM Shareholder Group, namely Dr. Yang and the entities controlled by him, including Morgancreek Investment Holdings Limited, Concord Medical, Ascendium Group Limited, Shanghai Huifu Technology Development Co., Ltd., Concord Hospital Management Group Limited, Shanghai Medstar, Tianjin Concord, Beijing Concord and Shanghai Xinhe, are still interested in 205,607,968 Domestic Shares and 96,518,100 H Shares, representing 42.18% of the Company's total issued share capital and voting rights of the Company's issued Shares in general meetings, the CCM Shareholder Group remains as our Controlling Shareholders.

To the best of the Company's knowledge, the Proxy Granters decided to terminate the relevant Voting Proxy Arrangement upon negotiation in good faith with the Proxy Granters. Despite the Proxy Termination, it is expected that each of the Proxy Granters will continue to engage in good faith discussions with Dr. Yang in respect of matters and resolutions of material interests to the Company. Additionally, as of the date of this announcement, Dr. Yang and the entities controlled by him has no intention to dispose any of the Shares held by him through his controlled corporations or reduce his shareholding in the Company in any substantial way, which will provide the Company with more broadly represented opinion and is believed to be beneficial to the Company in the long run.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares. When in doubt, Shareholders and potential investors of the Company are advised to seek advice from professional or financial advisers.

By order of the Board
Concord Healthcare Group Co., Ltd.*
美中嘉和醫學技術發展集團股份有限公司
YANG Jianyu
Chairman and Executive Director

Beijing, the People's Republic of China, July 31, 2024

As at the date of this announcement, the Board comprises (i) Dr. YANG Jianyu, Ms. FU Xiao, Mr. CHANG Liang and Mr. SHI Botao as executive Directors; (ii) Mr. WANG Lei and Mr. CHEN Hongzhang as non-executive Directors; and (iii) Ms. LI Xuemei, Mr. SUN Yansheng and Mr. NG Kwok Yin as independent non-executive Directors.

* *For identification purpose only*